Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 145158-71-0
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of tegaserod during breastfeeding. Because of the potential for serious adverse reactions in the breastfed infant, an alternate drug is preferred.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Linaclotide, Lubiprostone, Plecanatide, Prucalopride, Psyllium, Tenapanor
Substance Identification
Substance Name
Tegaserod
CAS Registry Number
145158-71-0
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.[Drugs. 2003]Review Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.Wagstaff AJ, Frampton JE, Croom KF. Drugs. 2003; 63(11):1101-20.
- Review Tegaserod for the Treatment of Irritable Bowel Syndrome.[Antiinflamm Antiallergy Agents...]Review Tegaserod for the Treatment of Irritable Bowel Syndrome.Madia VN, Messore A, Saccoliti F, Tudino V, De Leo A, De Vita D, Bortolami M, Scipione L, Pindinello I, Costi R, et al. Antiinflamm Antiallergy Agents Med Chem. 2020; 19(4):342-369.
- Tegaserod Maleate Suppresses the Growth of Gastric Cancer In Vivo and In Vitro by Targeting MEK1/2.[Cancers (Basel). 2022]Tegaserod Maleate Suppresses the Growth of Gastric Cancer In Vivo and In Vitro by Targeting MEK1/2.Wang Z, Chen Y, Li X, Zhang Y, Zhao X, Zhou H, Lu X, Zhao L, Yuan Q, Shi Y, et al. Cancers (Basel). 2022 Jul 23; 14(15). Epub 2022 Jul 23.
- Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).[Eur J Clin Pharmacol. 2001]Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).Appel-Dingemanse S, Hirschberg Y, Osborne S, Pommier F, McLeod J. Eur J Clin Pharmacol. 2001 Mar; 56(12):889-91.
- Review Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.[Clin Ther. 2003]Review Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.Rivkin A. Clin Ther. 2003 Jul; 25(7):1952-74.
- Tegaserod - Drugs and Lactation Database (LactMed®)Tegaserod - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...